Brief: Abliva Drug Candidate NV354 To Progress To Clinical Development Following Positive Regulatory Review

Abliva AB

17/09/2021 08:41

Sept 17 (Reuters) - Abliva AB  ABLI.ST :
    * ABLIVA DRUG CANDIDATE NV354 TO PROGRESS TO CLINICAL
DEVELOPMENT
FOLLOWING POSITIVE REGULATORY REVIEW
    * TEAM WILL NOW CONTINUE ASSEMBLING DOCUMENTATION NECESSARY
TO
SUPPORT A PHASE 1 CLINICAL START IN 2022.

Source text for Eikon:  ID:nMFN7WLF4b 
Further company coverage:  ABLI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))